Alison Pan

1.5k total citations
12 papers, 561 citations indexed

About

Alison Pan is a scholar working on Biotechnology, Oncology and Immunology. According to data from OpenAlex, Alison Pan has authored 12 papers receiving a total of 561 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Biotechnology, 6 papers in Oncology and 6 papers in Immunology. Recurrent topics in Alison Pan's work include Cancer Research and Treatments (8 papers), Cancer, Hypoxia, and Metabolism (5 papers) and Immune cells in cancer (4 papers). Alison Pan is often cited by papers focused on Cancer Research and Treatments (8 papers), Cancer, Hypoxia, and Metabolism (5 papers) and Immune cells in cancer (4 papers). Alison Pan collaborates with scholars based in United States and China. Alison Pan's co-authors include Weiqun Li, Rajinder Singh, Pingyu Ding, Dane A. Goff, Allan Torneros, Jing Zhang, Matt Duan, Sacha J. Holland, Christian Franci and Polly Pine and has published in prestigious journals such as PLoS ONE, Cancer Research and Molecular Biology of the Cell.

In The Last Decade

Alison Pan

11 papers receiving 551 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alison Pan United States	6	337	196	190	69	64	12	561
Mihalis S. Kariolis United States	8	398 1.2×	326 1.7×	241 1.3×	36 0.5×	96 1.5×	10	692
Mark J. Sinnamon United States	10	201 0.6×	180 0.9×	297 1.6×	52 0.8×	69 1.1×	12	625
Trisha R. Sippel United States	11	422 1.3×	253 1.3×	180 0.9×	29 0.4×	22 0.3×	11	687
Neetha Parameswaran United States	14	189 0.6×	225 1.1×	276 1.5×	22 0.3×	20 0.3×	23	562
Elisabetta Ruaro Italy	8	421 1.2×	228 1.2×	403 2.1×	123 1.8×	132 2.1×	9	755
Jodi L. Kroeger United States	12	320 0.9×	510 2.6×	191 1.0×	61 0.9×	16 0.3×	17	720
Keiichiro Sakuma Japan	11	165 0.5×	126 0.6×	404 2.1×	17 0.2×	29 0.5×	19	567
Agnete S. T. Engelsen Norway	13	203 0.6×	212 1.1×	252 1.3×	13 0.2×	42 0.7×	27	600
Tianqiang Jin China	10	246 0.7×	292 1.5×	247 1.3×	35 0.5×	54 0.8×	19	681

Countries citing papers authored by Alison Pan

Since Specialization

Citations

This map shows the geographic impact of Alison Pan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Pan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Pan more than expected).

Fields of papers citing papers by Alison Pan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison Pan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Pan. The network helps show where Alison Pan may publish in the future.

Co-authorship network of co-authors of Alison Pan

This figure shows the co-authorship network connecting the top 25 collaborators of Alison Pan. A scholar is included among the top collaborators of Alison Pan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison Pan. Alison Pan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Jiang, Xiaofan, Chiou‐Chung Yuan, Guo‐Jian Liu, et al.. (2025). A CD47 antibody with minimized erythrocyte and thrombocyte toxicities. Frontiers in Oncology. 15. 1686180–1686180.

Emberley, Ethan, Alison Pan, Jason Chen, et al.. (2021). The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma. PLoS ONE. 16(11). e0259241–e0259241. 33 indexed citations

Emberley, Ethan, Mark K. Bennett, Matthew Gross, et al.. (2018). Abstract 3509: The glutaminase inhibitor CB-839 synergizes with CDK4/6 and PARP inhibitors in pre-clinical tumor models. Cancer Research. 78(13_Supplement). 3509–3509. 12 indexed citations

Works, Melissa, Mark K. Bennett, Ethan Emberley, et al.. (2016). Abstract 552: Immuno-oncology agent CB-1158 is a potent and selective arginase inhibitor and causes an immune-mediated anti-tumor response. Cancer Research. 76(14_Supplement). 552–552. 10 indexed citations

Emberley, Ethan, Mark K. Bennett, Matt Gross, et al.. (2016). CB-839, a selective glutaminase inhibitor, has anti-tumor activity in renal cell carcinoma and synergizes with everolimus and receptor tyrosine kinase inhibitors. European Journal of Cancer. 69. S124–S124. 6 indexed citations

Steggerda, Susanne, Mark K. Bennett, Jason Chen, et al.. (2016). Abstract B045: Arginase inhibitor CB-1158 elicits immune-mediated antitumor responses as a single agent and in combination with other immunotherapies. Cancer Immunology Research. 4(11_Supplement). B045–B045. 2 indexed citations

Steggerda, Susanne, Ethan Emberley, Matthew Gross, et al.. (2016). Arginase inhibitor CB-1158 elicits immune-mediated anti-tumor responses as a single agent and enhances the efficacy of other immunotherapies. European Journal of Cancer. 69. S97–S97. 3 indexed citations

Gross, Matthew, Jason Chen, Ethan Emberley, et al.. (2015). Abstract A195: CB-1158 inhibits the immuno-oncology target arginase and causes an immune mediated anti-tumor response. Molecular Cancer Therapeutics. 14(12_Supplement_2). A195–A195. 4 indexed citations

Rodriguez, Mirna L.M., Winter Zhang, Mark K. Bennett, et al.. (2015). Abstract 4711: CB-839, a selective glutaminase inhibitor, synergizes with signal transduction pathway inhibitors to enhance anti-tumor activity. Cancer Research. 75(15_Supplement). 4711–4711. 4 indexed citations

10.

Boroughs, Lindsey K., Pei-Hsuan Chen, Ling Cai, et al.. (2015). Abstract 4710: Evaluation of the glutaminase inhibitor CB-839 in non-small cell lung cancer. Cancer Research. 75(15_Supplement). 4710–4710. 1 indexed citations

11.

Holland, Sacha J., Alison Pan, Christian Franci, et al.. (2010). R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer. Cancer Research. 70(4). 1544–1554. 429 indexed citations

12.

Stampfer, Martha R., Andrea Bodnár, James C. Garbe, et al.. (1997). Gradual Phenotypic Conversion Associated with Immortalization of Cultured Human Mammary Epithelial Cells. Molecular Biology of the Cell. 8(12). 2391–2405. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact